NO325947B1 - Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom. - Google Patents

Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom. Download PDF

Info

Publication number
NO325947B1
NO325947B1 NO19994778A NO994778A NO325947B1 NO 325947 B1 NO325947 B1 NO 325947B1 NO 19994778 A NO19994778 A NO 19994778A NO 994778 A NO994778 A NO 994778A NO 325947 B1 NO325947 B1 NO 325947B1
Authority
NO
Norway
Prior art keywords
agents
mycobacterial
atypical
rifabutin
clarithromycin
Prior art date
Application number
NO19994778A
Other languages
English (en)
Norwegian (no)
Other versions
NO994778D0 (no
NO994778L (no
Inventor
Thomas Julius Borody
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of NO994778D0 publication Critical patent/NO994778D0/no
Publication of NO994778L publication Critical patent/NO994778L/no
Publication of NO325947B1 publication Critical patent/NO325947B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19994778A 1997-04-01 1999-09-30 Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom. NO325947B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Publications (3)

Publication Number Publication Date
NO994778D0 NO994778D0 (no) 1999-09-30
NO994778L NO994778L (no) 1999-11-30
NO325947B1 true NO325947B1 (no) 2008-08-25

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994778A NO325947B1 (no) 1997-04-01 1999-09-30 Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom.

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
ATE446767T1 (de) * 1999-02-12 2009-11-15 Univ Washington Gm-csf zur behandlung von morbus crohn
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
ATE432691T1 (de) * 2000-03-28 2009-06-15 Sandoz Ag Geschmackmaskierte granulierte teilchen
ATE311358T1 (de) 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
PT1575951E (pt) 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
AU2004314731B2 (en) * 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
JP2007520495A (ja) 2004-02-06 2007-07-26 ボロディー トーマス ユリウス 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2816276A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
WO2009047801A1 (en) * 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
CA2721981A1 (en) * 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2011044140A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
EP2493471B1 (en) * 2009-10-26 2019-11-27 Thomas Julius Borody Novel enteric combination therapy
BR122014009845A2 (pt) 2010-04-26 2015-12-29 Salix Pharmaceuticals Ltd usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa
BR112013014827A2 (pt) 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas
TWI573590B (zh) 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
NZ704014A (en) 2012-07-27 2017-10-27 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
BR112022026615A2 (pt) 2020-06-30 2023-01-24 Redhill Biopharma Ltd Produtos combinados em dose tripla fixa de antibióticos, regime de dosagem, métodos e kits para tratamento de infecções por micobactérias pulmonares não tuberculosas
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
SI0971735T1 (sl) 2008-08-31
DK0971735T3 (da) 2008-07-07
JP2012126736A (ja) 2012-07-05
CY1109783T1 (el) 2013-09-04
JP2001524951A (ja) 2001-12-04
DE69839261D1 (de) 2008-04-30
NO994778D0 (no) 1999-09-30
CA2285923A1 (en) 1998-10-08
US6277836B1 (en) 2001-08-21
JP2008024713A (ja) 2008-02-07
WO1998043667A1 (en) 1998-10-08
ATE389417T1 (de) 2008-04-15
EP0971735B1 (en) 2008-03-19
CA2285923C (en) 2013-03-12
ES2303351T3 (es) 2008-08-01
IL132145A (en) 2005-11-20
EP0971735A1 (en) 2000-01-19
NZ500696A (en) 2002-05-31
EP0971735A4 (en) 2004-02-25
DE69839261T2 (de) 2009-03-26
IL132145A0 (en) 2001-03-19
AR012304A1 (es) 2000-10-18
NO994778L (no) 1999-11-30
PT971735E (pt) 2008-06-02

Similar Documents

Publication Publication Date Title
CA2285923C (en) Methods and compositions for treating inflammatory bowel disease
US6551632B2 (en) Methods and compositions for treating inflammatory bowel disease
Sakurai et al. Acute right-sided hemorrhagic colitis associated with oral administration of ampicillin
Russell et al. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice
US10328088B2 (en) Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
CN118766933B (zh) Aldisin化合物在制备治疗炎症性肠病的药物中的应用
WO2021112615A1 (ko) 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
JP2969017B2 (ja) 感染防御剤
AU774329B2 (en) Methods and compositions for treating inflammatory bowel disease
AU750813B2 (en) Methods and compositions for treating inflammatory bowel disease
Gangarosa et al. Search for a mass chemotherapeutic drug for cholera control: A study of vibrio excretion following single and multiple dose treatment
CN115279383A (zh) 用于治疗和预防胃肠炎症的普拉梭菌菌株cncm i-4573与pentasa®的组合
KR20170002454A (ko) 클라미디아 감염증 예방 치료제
CN117462551A (zh) 茚地那韦和/或其衍生物在制备抗结核药物中的应用
HK1161137A (en) Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
Dailianas et al. Efficacy of an inhibitor of leukotrienes production in patients with ulcerative colitis in remission
Domek et al. New antiulcer drug with anti-HP activity
Kamm Manipulation of enteric flora in clinical practice

Legal Events

Date Code Title Description
MK1K Patent expired